Your browser doesn't support javascript.
loading
Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study.
Gambardella, Valentina; Lombardi, Pasquale; Carbonell-Asins, Juan Antonio; Tarazona, Noelia; Cejalvo, Juan Miguel; González-Barrallo, Inés; Martín-Arana, Jorge; Tébar-Martínez, Roberto; Viala, Alba; Bruixola, Gema; Hernando, Cristina; Blasco, Inma; Papaccio, Federica; Martínez-Ciarpaglini, Carolina; Alfaro-Cervelló, Clara; Seda-García, Enrique; Blesa, Sebastián; Chirivella, Isabel; Castillo, Josefa; Montón-Bueno, José Vicente; Roselló, Susana; Huerta, Marisol; Pérez-Fidalgo, Alejandro; Martín-Martorell, Paloma; Insa-Mollá, Amelia; Fleitas, Tania; Rentero-Garrido, Pilar; Zúñiga-Trejos, Sheila; Cervantes, Andrés; Roda, Desamparados.
Afiliação
  • Gambardella V; Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Lombardi P; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
  • Carbonell-Asins JA; Division of Medical Oncology, Institute for Cancer Research and Treatment, IRCCS Candiolo, Candiolo, Italy.
  • Tarazona N; Bioinformatic and Biostatistic Unit, INCLIVA Biomedical Research Institute, Valencia, Spain.
  • Cejalvo JM; Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • González-Barrallo I; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
  • Martín-Arana J; Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Tébar-Martínez R; Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Viala A; Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Bruixola G; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
  • Hernando C; Bioinformatic and Biostatistic Unit, INCLIVA Biomedical Research Institute, Valencia, Spain.
  • Blasco I; Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Papaccio F; Precision Medicine Unit, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Martínez-Ciarpaglini C; Translational Oncology Unit, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Alfaro-Cervelló C; Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Seda-García E; Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Blesa S; Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Chirivella I; Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Castillo J; Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Baronissi, SA, Italy.
  • Montón-Bueno JV; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
  • Roselló S; Department of Pathology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Huerta M; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
  • Pérez-Fidalgo A; Department of Pathology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Martín-Martorell P; Precision Medicine Unit, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Insa-Mollá A; Translational Oncology Unit, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Fleitas T; Precision Medicine Unit, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Rentero-Garrido P; Translational Oncology Unit, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Zúñiga-Trejos S; Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Cervantes A; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
  • Roda D; Department of Biochemistry and Molecular Biology, University of Valencia, Valencia, Spain.
Br J Cancer ; 125(9): 1261-1269, 2021 10.
Article em En | MEDLINE | ID: mdl-34493820
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Análise de Sequência de DNA / Terapia de Alvo Molecular / Neoplasias Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Análise de Sequência de DNA / Terapia de Alvo Molecular / Neoplasias Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Espanha